Piper Sandler reiterates Adeptus Biotechnologies stock rating at overweight By Investing.com

Piper Sandler reiterated an Overweight on ADPT with a $20 price target versus the current $14.95 (≈34% upside; analyst consensus $20–$22). Adaptive Biotechnologies beat Q4 2025 estimates with EPS -$0.09 vs -$0.18 and revenue $71.7M (20.9% above the $59.33M estimate); MRD revenue grew 54% in Q4 and 46% for the year, while LTM gross margin was 74% and revenue rose 55% YoY. BTIG and TD Cowen raised price targets to $22 and $21 (Buys); shares have pulled back ~7% over the past week and are -8% YTD despite a +124% trailing 12-month return, presenting a cited buying opportunity.

Analysis

Adaptive’s immunosequencing platform creates a structural advantage in hematologic MRD by owning both the diagnostic signal and the central testing workflow; that vertically integrated footprint means incremental volume converts to gross profit faster than for pure-Lab-as-a-Service competitors. Second-order beneficiaries include large reference labs and consumable suppliers — sustained MRD adoption will disproportionately lift consumable demand (oligos, enzymes, instruments) and lab processing revenues, potentially creating capacity-led margin upside in the near term.

The chief near-term risks are payer and competitive dynamics rather than unit economics: a CMS or large-commercial payer reimbursement change, adverse LCD language, or a favorable external validation for tumor-informed NGS could compress ASPs or shift referrals within 6–18 months. Clinical guideline adoption and large oncology group referral patterns are binary catalysts — favorable guideline language can drive multi-quarter step-ups in test volume, while negative study outcomes or validation delays can remove the optionality baked into forward expectations.

Tactically, the most efficient way to capture upside while controlling downside is to express a 12–24 month conviction with asymmetric option structures or paired equity exposures that isolate platform share gains. A long/short pair versus other MRD-exposed names can neutralize macro biotech beta while letting the platform moat re-rate; monitoring leading indicators (ASP per test, volume growth ex-China, lab turnaround times, and payer contract updates) will give early signal for de-risking or adding.

Contrarian view: sell-side enthusiasm understates operational execution risk — scaling sequencing-heavy assays is non-linear and capital/ops friction could delay margin expansion despite robust demand. That makes structures that cap upfront cost but leave upside open (spreads, collars, pairs) the preferred way to participate rather than outright naked long exposure.

Key Decisions for Investors

• Core position (12–24 months): Accumulate ADPT equity sized as 1–2% of portfolio with a protective collar — buy shares and purchase a 12-month put ~30% OTM while selling a 12-month call ~60% OTM to fund cost; R/R: limited downside to put strike, capped upside to call strike, breakeven set near current basis.
• Asymmetric option trade (12–18 months): Buy a calendar or vertical call spread to capture clinical/guideline catalysts — long-dated (12–18mo) 60% OTM calls and sell nearer-term 120% OTM calls to finance; R/R: limited premium outlay with multi-bagger upside if volume/adoption accelerates.
• Pair trade to isolate platform alpha (6–12 months): Long ADPT equal notional / short an MRD/NGS competitor (e.g., NTRA or GH) to neutralize macro biotech exposure and capture relative share shifts; R/R: expect positive carry if immunosequencing wins hematologic share, but watch divergences on company-specific news.
• Event-driven short hedge (3–6 months): Buy 3–6 month OTM puts on ADPT ahead of major payer decisions or guideline committee votes to protect against binary downside; R/R: small premium protects against steep drawdowns from adverse reimbursement outcomes.